Better Therapeutics surges on additional data from diabetes trial

Better Therapeutics

28/07/2022 14:34

** Shares of digital therapeutics co Better Therapeutics
 BTTX.O  rise 56.2% to $2.39 premarket
    ** Co completes pivotal trial of its experimental digital
therapeutic for Type-2 diabetes, BT-001, and provides additional
data  urn:newsml:reuters.com:*:nBwc7vQ2ga
    ** Digital therapeutics deliver medical interventions
directly to patients using clinically evaluated software
    ** Additional secondary goals results from trial show that
BT-001 was durable, with hemoglobin A1c reductions continuing to
improve after 180 days of treatment - BTTX
    ** Says intends to submit request with U.S. FDA in Q3
seeking marketing authorization for BT-001 
    ** Stock down ~67% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))